Advanced Prostate DOG Meeting

Draft Agenda

May 1, 2010
1300-1430h
Location: TBD

1. Review of minutes from Advanced Prostate DOG Teleconference 27 January 2010 (5 Minutes)

2. Current planned/upcoming studies (20 minutes)
   a. Pre-Chemo: OGX-427 in chemo-naïve metastatic CRPC (TFRI funded, CUOG?) (Chi)
   b. First line: Docetaxel +/- OGX-011 (CUOG?) (Chi)
   c. Second line: Docetaxel +/- OGX-011 (CUOG?) (Hotte)
   d. IND.195: Phase II SB939 HDAC inhibitor single agent in metastatic CRPC (NCIC CTG) (Eigl)
   e. IND.XXX: Phase II PX-866 PI3K inhibitor single agent in metastatic CRPC (NCIC CTG) (TBD)
   f. Status of other agents (Discussion - Everyone)
      i. MDV3100
      ii. ZD4054
      iii. Dasatinib
      iv. Ipilumimab
      v. Sunitinib
      vi. VEGF-Trap
      vii. Denosumab
      viii. Alpharadin

3. Trial Proposals (50 Minutes)
   a. Randomized phase II of abiraterone + dutasteride vs. abiraterone (Emmenegger) (10 min)
   b. Randomized phase III of abiraterone + prednisone vs. placebo + prednisone in M0 CRPC (Chi) (10 min)
   c. Randomized phase III of continued vs. discontinued abiraterone after progression (Joshua) (10 min)
   d. Phase II of Degarelix for M0 CRPC (Malone) (10 min)
   e. MRC STAMPEDE Trial (Chi) (10 minutes)

4. Opportunities? (15 minutes) (Discussion – Everyone)
   a. Abiraterone and MDV3100 combinations
   b. Novel targeted agent combinations
   c. Biomarker driven (eligibility criteria or primary endpoint) protocols